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nases that regulate a vast array of fundamental cellular specific gene targeting approach to mutate PTEN in all
cardiomyocytes and skeletal muscle cells. Mice thatresponses, including proliferation, adhesion, cell size,
and protection from apoptosis (Toker and Cantley, 1997; have exon 4 and 5 of PTEN flanked by loxP sites by
homologous recombination (PTENflox; Suzuki et al., 2001)Stephens et al., 1993). These responses result from the
activation of membrane trafficking proteins and en- were mated with a CRE deleter line that expresses the
CRE transgene under the control of the muscle creati-zymes such as the phosphoinositide-dependent kinases
(PDKs), PKB/Akt, or S6 kinases by the key second mes- nine kinase promoter (mckCRE; Bruning et al., 1998).
We generated homozygous mutant mice that expresssenger PIP3 (Franke et al., 1997; Alessi et al., 1998;
Downward, 1998). Four different type I PI3Ks have been CRE and are floxed at both PTEN alleles (mckCRE-
PTEN/), heterozygous mice that express CRE but aredescribed three of which (PI3K, , ) are activated by
receptor tyrosine kinase pathways. PI3K is activated only floxed at one PTEN allele (mckCRE-PTEN/), and
control mice that do not express mckCRE but have bothby the  subunit of G-proteins and acts downstream
of G protein-coupled receptors (GPCRs; Toker and PTEN alleles floxed (PTENflox/flox). No phenotypic differ-
ences between mckCRE-PTEN/ and PTENflox/flox geno-Cantley, 1997). Recent genetic evidence in hematopoi-
etic cells indicates that PI3K is the sole PI3K that cou- types were observed. Western blotting showed a signifi-
cant reduction in the amount of PTEN protein in bothples to GPCRs (Sasaki et al., 2000; Hirsch et al., 2000;
Li et al., 2000). the heart as well as skeletal muscle, but no other tissues,
of mckCRE-PTEN/ mice (Figure 1A). The presence ofIn isolated cardiomyocytes, PI3K signaling has been
implicated as a component of cardiac hypertrophy and residual PTEN protein in mckCRE-PTEN/ mice is likely
due to PTEN expression in cardiac non-myocyte cellprotection of myocytes from apoptosis mediated by nu-
merous exogenous agonists and stresses (Rabkin et al., types such as endothelial cells or fibroblasts. Hearts
from mckCRE-PTEN/ mice showed no alteration in the1997; Schluter et al., 1999; Baliga et al., 1999; Kodama
et al., 2000). In transgenic mice, overexpression of con- expression of PI3K, PI3K, or PI3K catalytic subunits
nor changes in p85 expression (Figure 1B).stitutively active p110 results in increased heart size,
whereas cardiac overexpression of dominant-negative
p110 in mice resulted in smaller hearts without affect- Spontaneous Cardiac Hypertrophy
ing heart functions (Shioi et al., 2000). Furthermore, in PTEN-Deficient Hearts
PI3K activity is increased upon aortic constriction in Analysis of skeletal muscle from mckCRE-PTEN/ mice
mice (Naga Prasad et al., 2000), suggesting that both showed no gross abnormalities or any overt changes
tyrosine-based and GPCR-linked PI3Ks might play a in cell size compared to control mckCRE-PTEN/ or
role in the cardiac hypertrophy response. PTENflox/flox littermates. Overall body weights were com-
The tumor suppressor PTEN is a lipid phosphatase that parable between all three genotypes at all ages analyzed
dephosphorylates the D3 position of PIP3 (Maehama and (10 wks, 6 months, and 12 months). Moreover, there
Dixon, 1998). Thus, PTEN lowers the levels of the PI3K was no indication of diabetes and blood glucose levels
product PIP3 within the cells and antagonizes PI3K medi- did not differ between mckCRE-PTEN/, mckCRE-
ated cellular signaling. It has been recently shown that PTEN/, and PTENflox/flox littermates.
PTEN can regulate neuronal stem cell proliferation and Whereas skeletal muscle appeared normal, loss of
the cell size of neurons in brain-specific PTEN mouse PTEN in cardiac muscle resulted in greatly increased
mutants similar to patients with Lhermitte-Duclos dis- heart sizes in the mutant mckCRE-PTEN/ mice (Fig-
ease (Backman et al., 2001). Moreover, expression of ures 1C and 1D). Concordantly, there was a significant
dominant-negative PTEN in rat cardiomyocytes in tissue increase in heart/body weight ratios in the PTEN-defi-
culture results in hypertrophy (Schwartzbauer and Rob- cient hearts indicative of cardiac hypertrophy at 10
bins, 2001). Whether PI3Ks and PTEN can indeed control weeks and 12 months of age (Figure 2A). The increased
cardiac hypertrophy and heart functions in vivo is not heart size was already detectable in newborn mckCRE-
known. PTEN/ mice (not shown). Histologically, the increase
We investigated the role of the PI3K-PTEN signaling in heart size was observed throughout the heart (Figure
pathway in cardiac hypertrophy by studying PTEN-heart 1D). Interestingly, cardiac hypertrophy did not result in
muscle specific mutant mice, p110/, dominant-nega- fibrotic or structural changes in myocyte organization
tive p110 transgenic mice, and double-mutant mice. (Figure 1D) or perturbations in cardiomyocyte cell death
We show that two independent PI3K signaling pathways (not shown) even at 1 year of age indicating that loss
exist in cardiomyocytes that can be genetically uncou- of PTEN does not result in cardiac decompensation or
pled. While the tyrosine kinase-receptor p110-PTEN dilated cardiomyopathy.
pathway is a critical regulator of cardiac cell size, the To further analyze the cardiac hypertrophy in
GPCR-linked PI3K-PTEN signaling pathway modulates PTEN-deficient hearts, cardiomyocytes were isolated
heart muscle contractility. from adult mice to assess the individual cell size. Loss
of PTEN resulted in a marked increase in both the length
and width of cardiomyocytes as compared to controlsResults
(Figure 2B). The length-to-width ratio was unchanged
in these cells indicating that the cell size change wasGeneration of Cardiac Muscle Specific PTEN
Knockout Mice similar to that observed in physiologic hypertrophy
(Hunter and Chien, 1999). Pathological cardiac hypertro-Inactivation of PTEN in all cells results in early embryonic
lethality between day 6.5 to 9.5 (Suzuki et al., 1998; phy is characterized by a prototypical change in gene
expression patterns such as increased ANF, MyHC,Di Cristofano et al., 1998). We therefore used a tissue
PI3K Signaling and Heart Function
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BNP, and skeletal-actin expression, and a decrease in
MyHC (Hunter and Chien, 1999). However, no signifi-
cant alterations in the expression profile of these hyper-
trophic genes were observed with the exception of an
increase in MyHC (Figures 2C and 2D). Thus, loss of
PTEN in the myocardium induces hypertrophy without
the typical pathological changes in the gene expression
profiles or cardiac decompensation.
Activation of PI3K Signaling
in PTEN-Deficient Hearts
Since PTEN antagonizes the action of PI3K, we analyzed
whether the loss of PTEN in the hearts results in the
activation of downstream targets of PI3K signaling
(Downward, 1998). Loss of PTEN resulted in a significant
increase in the basal phosphorylation state of AKT/PKB
(Figures 2E and 2F). In addition, we found an increase
in the phosphorylation of GSK3 and p70S6K, both down-
stream targets of PI3K signaling (Figures 2E and 2F).
No apparent changes in the basal activation of ERK1/
ERK2 were observed between the mutant mckCRE-
PTEN/ mice and their mckCRE-PTEN/ and PTEN/
littermates (Figures 2E and 2F). These data establish
that loss of PTEN in cardiomyocytes results in increased
PI3K signaling leading to activation and phosphorylation
of multiple PI3K target molecules.
Loss of PTEN in the Heart Results in Decreased
Cardiac Contractility
To further characterize the role of PTEN in mutant
mckCRE-PTEN/ mice, we analyzed the hearts using
echocardiography. Consistent with the physiological
cardiac hypertrophy, echocardiography of PTEN-defi-
cient hearts revealed an increase in the anterior wall
thickness and an increase of the left ventricle mass
(LVM) at all ages analyzed (Figure 3A and Table 1). More-
over, the change in end diastolic dimension of the left
ventricle (LVEDD) reflected this overall enlargement of
PTEN-deficient heart. No difference in heart rate was
detected in the PTEN-deficient hearts (Table 1).
Surprisingly, assessment of cardiac function by echo-
cardiography revealed that mutant mckCRE-PTEN/
mice exhibited a dramatic reduction in cardiac contrac-
tility characterized by decreased fractional shortening
(FS), decreased velocity of circumferential fiber shorten-
ing (Vcfc), and reduced peak aortic outflow velocity
(PAV; Figures 3B, 3C, and Table 1). To confirm the echo-
cardiographic alterations, functional invasive hemody-
namic measurements were performed. Our hemody-
namic measurements showed that both dP/dT-max and
dP/dT-min were markedly reduced in the PTEN mutant
mice (Table 1), again indicating severe impairment ofFigure 1. Cardiac Hypertrophy in PTEN Mutant Hearts
contractile heart function. Despite marked reductions(A) Western blot analysis of proteins from different tissues of
mckCRE-PTEN/ and mckCRE-PTEN/ mice. in contractility at 10 weeks, there was no further de-
(B) Western blot analysis for p110, p110, p110, and p85 expres- crease in the function of the PTEN-deficient hearts ana-
sion levels in total heart lysates from 2 representative mckCRE- lyzed at 12 months of age (Table 1). In addition, there was
PTEN/ and two mckCRE-PTEN/ mice. no evidence of dilation, wall thinning, or tissue fibrosis in
(C) Representative heart sizes of 10-week-old mckCRE-PTEN/ and
older animals (Figure 1D, Table 1). These data show thatmckCRE-PTEN/ littermates.
PTEN controls cardiomyocyte size and heart muscle(D) Heart sections from 10 week (upper and middle images) and 1
contractility.year (lower images) old mckCRE-PTEN/ and mckCRE-PTEN/
mice. The middle and lower images show higher magnifications to
detect interstitial fibrosis (trichrome). LV  left ventricle; RV  right Increased Contractility in PI3K Mutant Mice
ventricle. The decrease in cardiac contractility found in the PTEN
mutant hearts suggested that increased PI3K signaling
Cell
740
Figure 2. Cardiac Hypertrophy and PI3K Activation
(A) Quantitation of heart/body weight ratios from 10-week-old mckCRE-PTEN/ (n  8) and mckCRE-PTEN/ (n  9) and 12 month old
mckCRE-PTEN/ (n  6) and mckCRE-PTEN/ (n  6) littermate mice.
(B) Increased cell sizes of cardiomyocytes isolated from 10-week-old mckCRE-PTEN/ mice. Representative images of isolated cardiomyocytes
and quantitation of cell sizes are shown. One hundred individual cells from three different mice were analyzed per group. ** p 	 0.01 between
genetic groups.
(C and D) Northern blot analysis and quantitation (mean values 
 SEM) of cardiac hypertrophy markers. GAPDH expression levels were used
as a loading control. Results from hearts isolated from 3 individual 10-week-old mckCRE-PTEN/ and 3 different, age-matched mckCRE-
PTEN/ littermate mice are shown.
(E and F) Increased AKT/PKB, GSK3, and p70S6K phosphorylation in total heart extracts from 10-week-old mckCRE-PTEN/ mice. Western
blot of the expression of phospho-AKT/PKB, phospho-GSK3, phospho-p70S6K, phospho-ERK1/2, and their respective loading controls.
Densitometric quantitation of phospho-AKT/PKB and phospho-GSK3 levels relative to total cellular AKT/PKB and GSK3. Mean values 

SEM are representative of 3 independent experiments. ** p 	 0.01 between genetic groups.
serves not only to increase cell size in the heart but to esized that the decreased heart function in PTEN mutant
mice is mediated by PI3K. We observed p110 proteinalso suppress basal heart function. Neither the p110
dominant-negative nor p110 constitutively active heart expression in total heart extracts of mice (Figure 1B) and
in isolated cardiomyocytes (Figure 3D). Loss of p110specific transgenic animals showed any alteration in
heart function (Shioi et al., 2000) suggesting that the expression does not alter the expression levels of p85,
p110, and p110 (Figure 3E). Moreover, p85 associatedeffect on contractility is mediated by PI3K isoforms other
than PI3K. Since several GPCR signaling pathways, PI3K activity in cardiomyocytes was comparable be-
tween p110/ and wild-type littermates using in vitroincluding adrenergic receptors (Rockman et al., 2002),
are important mediators of cardiac function, we hypoth- lipid kinase assays (not shown). There was also no ap-
PI3K Signaling and Heart Function
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Figure 3. Modulation of Cardiac Contractility in PTEN and p110 Mutant Hearts
(A) Left ventricular mass (LVM; mean values 
 SEM) in hearts from 10-week-old mckCRE-PTEN/ (n  8), wild-type (n  7), p110/ (n  7),
and mckCRE-PTEN/ p110 / (n  8) mice. ** p 	 0.01 between genetic groups.
(B) Percent fractional shorting (% FS) and velocity of circumferential fiber shortening (Vcfs) in 10-week-old mckCRE-PTEN/, wild-type,
p110/, and mckCRE-PTEN/ p110/ double-mutant mice. Mean values
 SEM were determined by echocardiography. ** p	 0.01 between
groups.
(C) M-mode echocardiographic images of contracting hearts in 10-week-old mckCRE-PTEN/, wild-type, p110/, and mckCRE-PTEN/
p110/ mice. Note that contracting hearts in mckCRE-PTEN/ p110/ double mutants are similar to that of p110/ mice.
(D) Western blot analysis for p110 expression in control and p110 deficient isolated cardiomyoctes. Note the smaller non-specific band.
(E) Western blotting for phosphorylated-AKT/PKB, total AKT/PKB protein, p85, p110, and p110 protein expression in total heart extracts.
(F) Representative heart sizes and heart/body weight ratios of 10 week old p110/ and p110/ littermates. Similar data, i.e, no change in
heart size, were obtained at 6 and 12 months of age.
(G) Western blot analysis of AKT/PKB phosphorylation and total AKT/PKB protein levels in hearts from individual p110/, mckCRE-PTEN/
and mckCRE-PTEN/ p110/ double-mutant mice.
parent difference in the expression or phosphorylation shortening (48.49 
 0.76 in wild-type (n  6) versus
55.16 
 0.33 in p110/ mice (n  6), and Vcfc (8.65 
of AKT/PKB (Figure 3E). Mice deficient for p110 were
found to have no alteration in heart size or left ventricle 0.20 in wild-type (n  6) versus 10.86 
 0.17 in p110/
mice (n  6)]. To ensure that the increase in cardiacmass (LVM) and displayed normal heart rates (Figures
3A, 3F, and Table 1). No structural alterations were ob- contractility observed in the p110 was due to the dis-
ruption of the gene and not an aberrant gene targetingserved in the hearts of p110/ mice using histological
analyses and there were no changes in the gene expres- event, we analyzed heart function in a second indepen-
dently generated mouse line deficient for p110 (Hirschsion profiles of the cardiac hypertrophy markers ANF,
MyHC, BNP, skeletal-actin, and MyHC. Thus, et al., 2000). All alterations in heart functions analyzed
were similar between the two independent p110 defi-whereas loss of PTEN results in cardiac hypertrophy,
PI3K has no role in the control of basal cardiomyocyte cient mouse lines. Specifically, the second p110mouse
line (Hirsch et al., 2000) had increased contractility assize.
Intriguingly, the hearts of p110 deficient mice dis- assessed by fractional shortening [48.07 
 0.68 in wild-
type (n  6) versus 56.47 
 0.87 in p110/ mice (n played a marked enhancement in contractility as as-
sessed by increased fractional shortening (FS), Vcfc, 6), and Vcfc (8.62 
 0.16 in wild-type (n  6) versus
11.35
 0.28 in p110/ mice (n 6)]. Moreover, hyper-and peak aortic outflow velocity (PAV; Figures 3B, 3C,
and Table 1). Hemodynamic measurements confirmed contractility persisted (Vcfc: 8.65 
 0.2 in wild-type ver-
sus 10.86 
 0.17 in p110/ mice; n  6; p 	 0.01)the increased heart contractility in p110/ mice (Table
1). Telemetry analysis of blood pressure in conscious and there was no evidence of cardiac hypertrophy or
increased myocardial fibrosis in 1-year-old mice (notmice revealed normal blood pressure in p110/ mice
(not shown). In addition, plasma epinephrine and norepi- shown). Thus, loss of PI3K results in a marked increase
in cardiac contractility.nephrin levels were not altered in p110/ mice com-
pared to controls [norepinephrin (59.63 
 9.99 in wild-
type (n  6) versus 61.28 
 8.82 in p110/ mice (n  PI3K Mediates Reduction of Heart Function
in PTEN-Deficient Hearts6), and epinephrin (4.65
 0.80 in wild-type (n 6) versus
4.28 
 0.55 in p110/ mice (n  6)]. The alterations in heart muscle contractility in p110
and PTEN mutant hearts were exactly opposite, thatTo determine if there are any long-term effects of this
increase in cardiac function in p110 deficient mice, we is loss of PTEN resulted in decreased heart functions
whereas loss of p110 leads to a marked enhancementanalyzed heart function by echocardiography in 1-year-
old mice. Similar to that observed in younger mice, there in cardiac contractility. To determine if the role of PTEN
in regulating cell size and heart function could be geneti-remained an increase in cardiac contractility [fractional
Cell
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cally uncoupled, we generated mice deficient for both
p110 and PTEN in the heart. Hearts from mckCRE-
PTEN/ p110/ double-mutant mice were signifi-
cantly enlarged as compared to wild-type and p110/
mutant mice (Figure 3A, Table 1). The extent of cardiac
hypertrophy in mckCRE-PTEN/ p110/ double-
mutant mice was similar to that observed for hearts from
mckCRE-PTEN/ single mutants (Figure 3A). Histologi-
cally, hearts from mckCRE-PTEN/ p110/ double-
mutant mice were also similar to that of mckCRE-
PTEN/ single mutant mice. Importantly, similar to
PTEN-deficient hearts, AKT/PKB was hyperphosphory-
lated in the hearts of mckCRE-PTEN/p110/double-
mutant mice (Figure 3G). Thus, loss of PI3K in PTEN-
deficient hearts has no affect on the increased AKT/
PKB phosphorylation and does not rescue the cardiac
hypertrophy phenotype.
However, unlike PTEN-deficient hearts, mckCRE-
PTEN/ p110/ double-mutant hearts were found to
be hypercontractile, as assessed by increased fractional
shortening (FS), Vcfc, and peak aortic outflow velocity
(PAV; Figures 3B, 3C, and Table 1). These improved
heart functions were similar to that of p110 single mu-
tant hearts. These data show that the defect in cardiac
contractility seen in the PTEN-deficient hearts is depen-
dent on the PI3K signaling pathway. Importantly, PTEN
regulated hypertrophy can be genetically uncoupled
from the cardiac contractility changes mediated by
PTEN-PI3K.
Reversal of Cardiac Hypertrophy in PTEN-Deficient
Hearts by a Dominant-Negative
p110 Transgene
The increase in cell size found in PTEN-deficient hearts
strongly resembles that seen in transgenic mice for heart
specific constitutively active p110 that couples to re-
ceptor tyrosine kinases (Shioi et al., 2000). Furthermore,
mice transgenic for heart-specific dominant-negative
p110 (DN-p110) have smaller than normal heart size.
We therefore generated mice deficient for PTEN in the
hearts and overexpressing the heart specific DN-p110
transgene. Hearts of mckCRE-PTEN/;DN-p110 mice
displayed a reduction in heart size similar to that seen
in single DN-p110 transgenic mice (Figures 4A and 4B).
The presence of the DN-p110 transgene also corre-
lated with a decrease in the basal level of AKT/PKB
activation in the absence or presence of a functional
PTEN gene (Figure 4C). However, whereas overexpres-
sion of DN-p110 on a wild-type background affects
heart size but has no apparent effect on heart function,
hearts from mckCRE-PTEN/;DN-p110 displayed a
marked decrease in contractility (Figures 4D, 4E, and
Table 1). Taken together, these data show that PI3K
signaling modulates basal cell size of cardiomyocytes
while PI3K signaling controls basal cardiac contrac-
tility.
PI3K and PTEN Control Contractility
in Single Cells
To further analyze these in vivo contractility defects, we
elucidated whether loss of PTEN and PI3K can affect
contractility of a single adult cardiomyocyte in vitro. In
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Figure 4. Heart Sizes and Functions in mckCRE-PTEN/ DN-p110 Mice
(A) Representative heart sizes of 10-week-old wild-type, DN-p110, and mckCRE-PTEN/ DN-p110 littermates.
(B) Left ventricular mass (LVM; mean values 
 SEM) in hearts from 10 week old mckCRE-PTEN/ (n  8), wild-type (n  6), DN-p110 (n 
4), and mckCRE-PTEN/ DN-p110 double transgenic (n  4). ** p 	 0.01 between genetic groups.
(C) Western blot analysis of AKT/PKB phosphorylation and total AKT/PKB protein levels in hearts from wild-type (lane 1), DN-p110 single
transgenic (lane 2), and mckCRE-PTEN/ DN-p110 double-transgenic (lane 3) mice.
(D) M-mode echocardiographic images of contracting hearts in 10-week-old wild-type, mckCRE-PTEN/, and mckCRE-PTEN/ DN-p110
double-transgenic mice.
(E) Percent fractional shorting (% FS) and velocity of circumferential fiber shortening (Vcfs) in 10-week- old mckCRE-PTEN/ (n  8), wild-
type (n  6), DN-p110 (n  4), and mckCRE-PTEN/ DN-p110 double-transgenic (n  4) mice. Values (mean 
 SEM) were determined by
echocardiography. ** p 	 0.01 between groups.
hemodynamic data, it was found that PTEN deficient relaxation in p110 deficient cardiomyocytes compared
to control cells despite a marked increase in peak con-cardiomyocytes display a reduction in contractility as
determined by a reduction in percent cell shortening traction (Table 2). Cardiac relaxation is modulated via
cAMP dependent pathways, where cAMP activatesand positive and negative dL/dTs as compared to wild-
type cardiomycoytes (Figures 5A and 5B; Table 2). Con- PKA, which then inhibits phospholamban (PLB) leading
to increased sarcaplasmic reticulum calcium ATPaseversely, p110 deficient myocytes displayed an increase
in contractility (Figures 5A and 5B; Table 2). Cardiomyo- (SERCA) activity (Brittsan and Kranias, 2000). Moreover,
it has previously been shown in vascular smooth musclecytes deficient for both PTEN and p110 display in-
creased contractility despite the hypertrophy present cells that pharmacological inhibition of PI3K can lead
in these cells (Figures 5A and 5B; Table 2). Moreover, to increases in cAMP levels (Komalavilas et al., 2001).
treatment of wild-type myocytes with the PI3K inhibitor To determine if alterations in cAMP levels may also be
LY294002 lead to a significant increase in cardiomyo- contributing to the phenotype observed here, we mea-
cyte contractility. In p110 deficient cardiomyocytes, sured baseline cAMP levels in isolated myocytes. In
addition of LY294002 had no effect on the already in- unstimulated PTEN-deficient cardiomyocytes, cAMP
creased contractility (Figure 5B; Table 2). These in vitro levels were significantly reduced (Figure 5C). Con-
data show that independent of exogenous agonists versely, an increase in cAMP levels was detected in
PTEN and PI3Kcontrol basal cardiomyocyte contractil- isolated cardiomyocytes deficient for p110 (Figure 5C).
ity within a single cell. Importantly, treatment of PTEN-deficient and wild-type
cardiomyocytes with the PI3K inhibitor Wortmannin re-
sulted in a marked increase of cAMP to levels observedPI3K Modulates Baseline cAMP Levels
in Cardiomyocytes in p110 deficient cells (Figure 5C). Induction of cAMP
production in response to the adenylate cyclase agonistOne intriguing aspect of the in vitro contractility data
is that there was a significant increase in the rate of forskolin was comparable among all genotypes ana-
Cell
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Figure 5. Single Cell Contractility and cAMP Production
(A and B) Basal contractility of single cardiomyocytes isolated from mckCRE-PTEN/, wild-type, p110/, and mckCRE-PTEN/ p110/
double-mutant mice. In (A), representative contractions from single cells are shown. In (B), mean percentage shortening (
 SEM) of at least
15 different single cells from 3 different hearts per genotype are shown in the presence and absence of the PI3K inhibitor LY294002 [30 M].
** p 	 0.01 between groups.
(C) Basal cAMP levels (mean
 SEM) in purified cardiomyocytes from mckCRE-PTEN/, wild-type, and p110/ mice (n 4 for each genotype).
Samples were either left untreated () or treated with wortmannin (wort, ). * p 	 0.05 between groups.
(D) Activation of adenylate cyclase via forskolin [25 M] increases the levels of cAMP production (mean 
 SEM) in mckCRE-PTEN/, wild-
type, and p110/ cardiomyocytes to a similar extent.
(E) Inhibition of cAMP dependent functions via Rp-cAMPS [25 M] reduces cell shorting (contractility) in single wild-type and p110/
cardiomyocytes. Mean values (
 SEM) of percent shortening in the presence of Rp-cAMPS (left image) and percent decrease in contractility
using Rp-cAMPS are shown. ** p 	 0.01 between groups.
lyzed (Figure 5D) indicating that the basal machinery for activation of downstream targets using Rp-cAMP. In
wild-type adult mouse cardiomyocytes, treatment withcAMP production is operational in all genotypes. These
genetic data show that PI3K and PTEN modulate cAMP Rp-cAMP lead to a marked decrease in contractility
(Figure 5E; Table 2). Importantly, treatment of p110production in cardiomyocytes.
To determine if these alterations in cAMP levels con- deficient cardiomyocytes with the cAMP blocker lead
to a greater reduction in contractility as compared totribute to altered contractility, we measured contractility
in single cells following blockade of cAMP-dependent wild-type cells such that the difference in the resultant
Table 2. Contractility of Isolated Single Cardiomyocytes
mckCRE- Wildtype p110/ Wildtype p110/
mckCRE- PTEN/ (LY294002) (LY294002) (Rp-CAMPs) (Rp-CAMPs)
Wildtype PTEN/ p110/ p110/ (30M) (30M) (25M) (25M)
Resting Length, m 121.7
 3.1 146.7
 2.9a 123.6
 3.2 147.3 
 2.4a 123.8 
 2.1 124.1 
 3.4 120.6 
 2.6 122.1 
 2.2
% Shortening 11.4
 0.51 7.1 
 0.43a 17.4 
 1.1a 16.6 
 1.2a 15.6
 0.97a 16.5 
 1.3a 9.58 
 0.37a 12.1 
 0.41b
dL/dT, m/s 339 
 17.2 224 
 14.3a 797 
 45a 723 
 42a 503 
 22.5a 717 
 53a 278 
 12.3a 496 
 21.3b
dL/dT, m/s 358 
 18.1 242 
 16.4a 960 
 56a 889 
 58a 521 
 25.8a 912 
 63a 289 
 17.2a 579 
 31.6a
TPS, ms 55.3 
 3.2 49.4 
 3.8 48.7 
 2.2 50.2 
 2.4 50.3 
 2.9 53.3 
 3.1 54.7 
 2.8 53.1 
 2.6
T90R, ms 71.9 
 3.6 76.7 
 4.5 54.7 
 2.8a 51.3 
 2.6a 50.1 
 2.8a 50.5 
 2.5a 76.9 
 3.2 68.8 
 3.7b
a p 	 0.01 versus wildtype cells.
b p 	 0.01 versus untreated p110/.
Mean 
 SEM are shown; n  15 cells from 3 hearts for each group. dL/dT max  maximum 1st derivative of the change in cell length/time;
dL/dT  minimum 1st derivative of the change in cell length/time; TPStime to peak shortening; T90Rtime to 90% relaxation.
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Figure 6. PI3K and -Adrenergic Signaling
(A) GRK kinase activities from fractionated heart lysates from individual mckCRE-PTEN/ and mckCRE-PTEN/ mice were determined using
in vitro kinase assays and rhodopsin as substrate. Since GRKs are recruited to membranes, data from cytosolic and membrane fractions are
shown. C  control using recombinant GRK2. The lower image shows a Western blot of total GRK2/3 expression levels in the hearts.
(B) -AR densities were determined using ICYP as a ligand as described in Experimental Procedures (n  7 for wild-type; n  5 for mckCRE-
PTEN/; and n  5 for p110/).
(C) Induction of cAMP production in response to the selective 2-adrenergic receptor agonist zinterol. Note that zinterol has no detectable
effect on 2-AR induced cAMP levels in wild-type cardiomyocytes (n  5) but significantly increases cAMP levels in p110/ cardiomyocytes
(n  5). * p 	 0.05 between groups.
(D) Induction of cAMP production in response to 1-adrenergic receptor stimulation. Both wild-type (n  4) and p110/ cardiomyocytes
(n  4) respond equally to isoproterenol. 2-AR were blocked with pretreatment of ICI 118,551.
(E) Western blot analysis of phosphorylated phospholamban (P-PLB) and total phospholamban (PLB) in wild-type and p110/ cardiomyocytes
in response to different concentrations of the selective 2-AR agonist zinterol. C  control. Note the increased phosphorylation of PLB in
unstimulated p110/ cardiomyocytes that mirrors increased basal cAMP levels in these cells. One representative experiment is shown.
contractility of wild-type and p110 deficient cells The G protein coupled 2-adrenergic receptors (2-
AR) are linked to both Gs and Gi G-proteins that cantreated with Rp-cAMP was greatly reduced compared
to untreated cells (Figure 5E; Table 2). In addition, the either increase (Gs) or decrease (Gi) cAMP levels and
rate of relaxation in p110 deficient cardiomyocytes heart muscle contractility (Kuznetsov et al., 1995; Xiao
treated with Rp-cAMP was reduced to wild-type levels et al., 1999; Rockman et al., 2002). To determine if PI3K
(Table 2). These data indicate that alterations in baseline can modulate cAMP production following GPCR stimu-
cAMP levels contribute to the increased contractility in lation, we purified neonatal cardiomyocytes from both
p110/ hearts. wild-type and p110/ hearts and stimulated these
cells with the 2-AR selective agonist zinterol. As de-
scribed previously for adult rat myocytes (Kuznetsov etPI3K and -Adrenergic Signaling
al., 1995), stimulation of the 2-AR had no affect onIt has been previously shown that PI3K can bind to
cAMP levels in wild-type mouse cardiomyoctes. By con-GPCR-kinase 2 (GRK2; Naga Prasad et al., 2001a), a
trast, selective stimulation of the 2-AR in p110/kinase that mediates desensitization of GPCRs like
cardiomyocytes resulted in a marked increase in cAMP-adrenergic receptors (-AR; Lefkowitz, 1998). Thus,
levels (Figure 6C). Conversely, stimulation of 1-AR re-we speculated that -adrenergic signaling may be af-
ceptors resulted in a similar increase in cAMP levelsfected in p110/ hearts, and that alterations of PI3K
in both wild-type and p110-deficient cardiomyocytesactivity may affect GRK activity and/or -AR expression.
demonstrating selectivity for the action of PI3K onUsing an in vitro kinase assay, GRK activity in both
cAMP production (Figure 6D).cytosolic and membrane-associated fractions of
In cardiomyocytes, increased cAMP levels result inPTEN-deficient hearts was comparable to that of control
enhanced contractility via activation of PKA and subse-hearts (Figure 6A). Total protein levels of GRK2 were
quent phosphorylation of phospholamban (PLB) in thealso comparable (Figure 6A). Radiolabeled ligand bind-
sarcoplasmic reticulum (Brittsan and Kranias, 2000).ing assays showed that there is also no detectable differ-
Similar to cAMP production, no alteration of PLB phos-ence in the density of -AR receptors or their affinity
phorylation could be detected in wild-type cells uponfor the -AR ligand ICYP in the PTEN- or p110-deficient
stimulation with the 2-AR agonist zinterol (Figure 6E).hearts as compared to wild-type mice (Figure 6B). These
However, when p110/ cardiomyocytes were stimu-data imply that changes in contractility of PTEN and
lated with the same 2-AR agonist, a dose dependentp110-deficient hearts are not due to alterations in base-
increase in PLB phosphorylation was observed. Thus,line -adrenergic receptor levels or the modulation of
GRK activity. in addition to its role in baseline cardiac contractility,
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loss of p110 expression releases the inhibition of the plays an important role in the regulation of basal cardio-
myocyte size in vivo.2-AR thereby permitting receptor-induced cAMP pro-
duction and subsequent PLB-phosphorylation. Our results show that PI3K has no role in the homeo-
static control of cardiomyocyte cell size. Yet many ago-
nists used to induce PI3K-dependent cardiomyocyte
Discussion hypertrophy in vitro are GPCR agonists (Rabkin et al.,
1997; Schluter et al., 1999). Moreover, PI3K is activated
We elucidated the roles of PI3K-PTEN signaling in car- in pressure overload induced hypertrophy in vivo (Naga
diac hypertrophy and heart functions in PTEN-heart Prasad et al., 2000), implying a role for PI3K in agonist-
muscle specific mutant mice, p110 knockout, domi- induced cardiac hypertrophy. Thus, it will be interesting
nant-negative p110 transgenic mice, and double-mu- to determine if PI3Kmay play a role in agonist-induced
tant mice. We show that the tyrosine kinase-receptor hypertrophy in vivo following stimulation of GPCRs.
p110-PTEN pathway is a critical regulator of cardiac
cell size. Intriguingly, our data revealed that the
Regulation of Heart Muscle ContractilityPTEN-PI3K signaling pathway regulates heart muscle
by PI3K and PTENcontractility via GPCRs. This contractility phenotype is
While the cardiac hypertrophy observed in the PTENpresent in single cardiomyocytes and dependent on
deficient hearts was similar to that seen in p110 trans-cAMP signaling. PI3K regulates cardiac function by
genic mice, PTEN deficient hearts surprisingly also dis-negatively regulating cAMP levels and phospholamban
played a dramatic decrease in cardiac contractility. Con-phosphorylation upon 2-adrenergic receptor stimula- versely, PI3K deficient hearts exhibited an increase intion. These data show that the tumor suppressor PTEN
cardiac contractility. These data reveal that PI3K-PTENhas an important in vivo role in GPCR signaling and that
signaling control heart muscle function in vivo. Impor-PTEN and PI3K signaling control heart function.
tantly, the data presented here show that PI3K can
modulate contractility in the absence of exogenous ago-
nists. These contractility changes are at least in partPTEN and Heart Muscle Size
The cardiac hypertrophy in PTEN deficient hearts is simi- mediated by alteration in cAMP levels.
An interesting conceptual issue arises from this work:lar to that in mice overexpressing a constitutively active
p110 transgene in the heart (Shioi et al., 2000). Like how do these different PI-3 kinases trigger distinct cellu-
lar responses? If the function is at the level of lipidthese transgenic mice, the hypertrophy found in PTEN
deficient hearts displayed features characteristic of phosphorylation, are the lipids different or do they have
different localization? For instance, both the spatial andphysiological hypertrophy, such as increase in both the
length and width of the myocytes, no fibrotic changes, temporal organization of signaling complexes is crucial
for the specificity of outcomes (Milligan and White,and no decompensation into dilated cardiomyopathy
(Hunter and Chien, 1999). The reversal of heart size in 2001). Or is it the proposed protein kinase activity of
these enzymes? While both PI3K and PTEN have beenthe PTEN deficient hearts that expressed a dominant-
negative PI3K transgene indicates that it is this isoform shown to possibly act on protein substrates in vitro, no
common protein substrates have been identified (Bon-of PI3K that modulates basal cell size in cardiomyo-
cytes. Moreover, it does not appear that any other PI3K deva et al., 1998; Tamura et al., 1998). Thus, most likely
the phenotypes observed here are due to the lipid ki-isoform can compensate for the loss of PI3K function
in vivo. It should be pointed out that it is possible that nase/phosphatase activity of these enzymes. Hearts de-
ficient in both PTEN and PI3K also displayed increasedthis transgene interferes with not only p110, but also
p110 and p110, as all of these require p85 activity cardiac contractility indicating that increased PIP3 gen-
erated via PI3K causes the decrease in cardiac con-which is likely sequestered as a result of the transgene
expression. Nevertheless, these data does show a dif- tractility seen in the PTEN deficient hearts. Moreover, it
is possible that the different receptors recruit differentferential action of class Ia and class Ib PI3Ks, as it is
unlikely that this transgene interferes with p110 func- downstream targets for the same phospholipids.
2 adrenergic receptors are coupled to both Gs andtion. This is further supported by the absence of any
observable alteration in cardiac contractility in mice ex- Gi signaling (Rockman et al., 2002). The opposing ef-
fects of these two G protein subunits result in no globalpressing the DN-p110 transgene.
Previously, PI3K signaling has been implicated in cell net effect on cardiac contractility or cAMP production
upon receptor stimulation (Kuznetsov et al., 1995; Xiaosize regulation in other tissues and organisms such as
Drosophila (Scanga et al., 2000). Mice deficient for p70S6K et al., 1999). It has been shown, however, that if the Gi
subunit is inhibited, a Gs response and an increasehave reduced body size due to a reduction in cell size
(Shima et al., 1998). Recently, brain specific disruptions in myocyte contractility ensues (Xiao et al., 1999). Our
results indicate that loss of PI3K in heart muscle cellsof PTEN have been reported which result in the increase
in neuronal cell size (Backman et al., 2001). Moreover, relieves an inhibition resulting in cAMP production and
PLB phosphorylation upon 2 AR agonist stimulationtransgenic expression of activated AKT/PKB in mouse
heart leads to a hypertrophic phenotype and this pheno- consistent with an inhibition of Gi. In this scenario, loss
of PI3K would result in a lack of Gi cAMP inhibitiontype can be inhibited with a DN-p110 transgene (Shioi
et al., 2002; Matsui et al., 2002). This is consistent with and a subsequent increase in cAMP levels and PLB
phosphorylation resulting in the inhibition of PLB andour data on the differential modulation of AKT/PKB
phosphorylation in PTEN but not PI3K mutant hearts. increased SERCA function effectively enhancing con-
tractility (Zvaritch et al., 2000; Frank and Kranias, 2000).Thus, it appears that AKT/PKB and p70S6K signaling
PI3K Signaling and Heart Function
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cent Electronics) was used to track myocyte contractions at 240Additional molecular mechanisms controlling cAMP lev-
Hz. Steady-state contractions were recorded at 1 kHz following aels and PLB phosphorylation in a PTEN-PI3K depen-
4 min equilibrium period using a Phillips 800 camera system (240dent manner cannot be excluded.
Hz) and Felix acquisition software (Photon Technologies Inc.). Cardi-
In heart failure, 1-AR densities decrease leading to omyocyte length, percent fractional shortening, shortening rate
a greater prominence of 2 adrenergic signaling (Naga (dL/dT), and relaxation rate (dL/dT) were determined at baseline.
Myocytes were incubation with LY294002 (30 M; Calbiochem) andPrasad et al., 2001b). Furthermore, it has been shown
Rp-cAMPS (25 M; Sigma/RBI) for 10 min and recordings werethat increased PLB activity is a critical regulator of de-
made during continuous perfusion of the drug dissolved in Tyrode.creased contractility in dilated cardiomyopathy (Mina-
In all experiments, phosphodiesterase activity was inhibited by pre-misawa et al., 1999). It is not known if PI3K is upregu-
treating the cells with theophylline (100 M) for 30 min prior to
lated in heart failure; however, it is known that p110 stimulation. Wortmannin treatment (100 nM) was initiated at the time
expression can be induced in pressure overload hyper- of theophylline addition. Zinterol (Bristol-Myers Squibb) stimulation
was carried out at RT for 10 min. Forskolin (Sigma) was used at 25trophy (Naga Prasad et al., 2000). Thus, in the presence
M. Isoproterenol (Sigma) stimulation was carried out at RT for 10of increased PI3K, 2 adrenergic signaling could lead
min, following 5 min pretreatment of ICI 118,551 (Sigma/RBI)to a reduction in cardiac contractility. It would be inter-
(107M). cAMP was measured by RIA according to the supplier’sesting to determine the role PI3K-regulated contractil-
protocol (Amersham).
ity in heart diseases. Moreover, inhibition of PI3K may
lead to better cardiac contractility in heart failure. GRK Activity and -Adrenergic Receptor Binding
GRK activity was measured by rhodopsin phosphorylation as de-
Experimental Procedures scribed. Hearts were homogenized in 20 mM Tris [pH 7.3], 0.8 mM
MgCl2, and 2 mM EDTA. Membrane fractions were isolated by centri-
Mutant Mice fuging at 40,000 g for 30 min at 4C. Three hundred g and twenty
The generation and genotyping of the PTEN-floxed, mckCRE, p110, g of protein were assayed for cytosolic and membrane fractions,
and DN-p110 mice have been previously described (Suzuki et al., respectively. -AR density and affinity for its ligand ICYP (3-Iodocya-
2001; Bruning et al., 1998; Sasaki et al., 2000; Shioi et al., 2000; nopindolol [125I]) were determined by equilibrium radio-ligand bind-
Hirsch et al., 2000). Only littermate mice were used as controls. Mice ing assays on sarcolemmal membranes prepared from ventricular
were bred and maintained following institutional guidelines. myocardium as described (Steinberg et al., 1995). Briefly, assays
were performed with 30 g membrane protein and ICYP (5-250 pM)
in the absence or presence of 0.1 M unlabeled propranolol toProtein and mRNA Expression Analyses
determine non-specific binding in a final volume of 1 ml for 60Northern and Western blotting were carried out as described (Crack-
min at 37C. ICYP bound to membranes was separated from free,ower et al., 2002) using antibodies to PTEN (Cascade), p110, p110,
unbound ICYP by rapid vacuum filtration over glass-fiber filters (Gel-p110 (Santa Cruz), p85 (Upstate Biotechnologies), phospho-AKT/
man A/E).PKB (S473), AKT/PKB, phospho-GSK3, GSK3, phospho-p70S6K,
phospho-ERK1/2, ERK1/2, phospho-phospholamban (Serine16),
phospholamban (Cell Signaling Technology), and GAPDH (Research Acknowledgments
Diagnostics). For immunoprecipitations, lysates were incubated
with anti-GRK2/3 Abs (Upstate Biotechnologies) conjugated with We thank T. Wada, K Bachmaier, and S. Backman for helpful discus-
Sepharose beads for 16 hr at 4C. Immunoprecipitates were sepa- sions. This study was supported by Amgen and by grants from
rated using SDS–PAGE gel electrophoresis, transferred onto mem- American Heart Association and the NIH HL28958 to S.F.S. S.I. is
branes, and immunoblotted. supported by an NIH Grant, HL 65742. J.M.P. was supported by
Amgen Inc., the National Cancer Institute of Canada, and IMBA,
Vienna. J.M.P. holds a Canadian Research Chair in Cell Biology.Heart Morphometry, Echocardiography,
M.A.C. is supported in part by a Canadian Institutes of Health Re-and Hemodynamic Measurements
search fellowship.For heart morphometry, hearts were arrested with KCL, fixed with
10% buffered formalin, and embedded in paraffin. Fibrosis was
Received: February 27, 2002analyzed using trichrome staining and quantitative morphometry
Revised: August 15, 2002using color-subtractive computer assisted image analysis. Echocar-
diographic assessments and invasive hemodynamic measurements
were carried out as described (Crackower et al., 2002). Catechola- References
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